Drug Approval | August 06, 2023
Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP
The product is being launched in August 2023
The product is being launched in August 2023
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
This product will be launched through Granules Consumer Health (GCH) division
Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S.
Granules now has a total of 58 ANDA approvals from US FDA
Metoprolol Succinate ER Tablets are indicated for the treatment of hypertension in order to lower blood pressure.
The product is expected to be launched in June 2023
Venlafaxine HCl extended-release capsules are indicated for the treatment of: Major Depressive Disorder
Subscribe To Our Newsletter & Stay Updated
